American Society of Hematology

Company Presentations

The following company presentations took place at the 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases.

Thursday, July 12

Phase 3 Development of Tab-cel™, an Off-the-Shelf, Allogeneic T-Cell Immunotherapy for Epstein-Barr Virus-Associated Lymphoma

Presented by Atara Biotherapeutics

This presentation will highlight an initiated phase 3 study of an off-the-shelf, allogeneic T-cell immunotherapy in oncology for the treatment of Epstein-Barr virus-associated lymphoma. This therapy was developed at an academic center and has progressed through late-stage development for posttransplant lymphoproliferative disorder, a rare hematologic malignancy. Key takeaways include an overview of therapy and characterization relative to other cell therapy approaches and insights about Atara’s unique, off-the-shelf allogeneic T cells.

Cellular Therapy: How Do You Streamline Commercialization?

Presented by Beckman Coulter Inc.

With the growing number of clinical trials, it is becoming clear that immunotherapy is the future of regenerative medicine. For example, CAR T looks great in the clinic, but how do you commercialize it? Constant innovation is necessary to eliminate inefficient workflows, sources of variability, and user introduced errors. Beckman Coulter Life Sciences’ integrated technologies are uniquely positioned to reshape the manufacturing and quality control workflow without compromising data quality or compliance.

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination With Daratumumab Over CAR-Based Approaches

Presented by Unum Therapeutics

ACTR technology is a universal, engineered T-cell therapy that combines the Fc receptor with endogenous T-cell domains. ACTR T-cell activity is regulated through antibody administration and is not susceptible to target-mediated autolysis. Findings demonstrate the adaptability of the ACTR platform to function in combination with daratumumab and bypass the challenges of scFv-based CAR T-cell production to effectively target CD38-positive malignancy.

back to top

Friday, July 13

Toward complete and durable regressions in multiple myeloma patients with an anti-BCMA CAR T cell

Presented by Bluebird Bio

Anti-BCMA CAR T cells can cause complete and durable regressions in some heavily pretreated multiple myeloma patients. These data will be discussed together with approaches that may improve durable clinical responses.

Chromosome Conformation Monitoring for Prognostic Stratifications of Non-Responders to Cancer Immunotherapies: Deconvolution of Epigenetic Data With EpiSwitch

Presented by Oxford Biodynamics Plc

This presentation will provide an introduction to epigenetic non-invasive biomarker modality, with examples of validation studies for predictive stratifications for PD-1/PD-L1 treatments.

back to top